Ryan Specialty (RYAN) Q2 Earnings: What To Expect

Ryan Specialty (NYSE: RYAN) is set to report Q2 earnings Thursday after market close. The prior quarter revenue was $795.2M, up 15.2% YoY, and it beat revenue and EPS expectations. For Q2, analysts expect 1.8% YoY revenue growth. The article cites peer results from Marsh and Brown & Brown and notes RYAN is near a $45.88 average price target.

Original reporting
Published Jul 29, 2026, 4:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 4:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ryan Specialty (RYAN) Q2 Earnings: What To Expect — source image
Decision brief

The 30-second read

$RYANNeutralMed
01

Why it matters

Traders should focus on whether revenue growth stays near the slowing consensus (1.8% YoY) versus last year’s 23% increase, and whether EPS quality supports the prior beat pattern.

02

Market read

This is a pre-earnings setup with consensus growth expectations and peer reaction context, implying higher near-term volatility around the release.

03

What to watch

The article does not discuss margin, underwriting/fee drivers, or guidance details, which are often the real swing factors for specialty insurance brokers’ earnings reactions.

Relevance 4/10Novelty 4/10Timing: Ahead of Ryan Specialty’s Q2 earnings release after market hours this Thursday.

Background

The article frames Ryan Specialty’s upcoming Q2 earnings, noting last quarter’s revenue beat and EPS beat, plus that the company has missed revenue estimates multiple times over the last two years.

Company-level read

Ticker impact

$RYANNeutralMedium confidence
Context

Ryan Specialty reports Q2 this Thursday after the close, with consensus expecting revenue growth to slow to 1.8% YoY.

Expected impact

Likely elevated volatility into the print; direction depends on whether revenue growth and EPS beat versus the slowing 1.8% YoY expectation.

Evidence & confidence

The article provides timing (after-hours Thursday) and the consensus growth slowdown, but it does not disclose any new guidance, filings, or analyst rating changes beyond general reconfirmation.

Market effects

Professional services read-through is mixed, with Marsh down after results and Brown & Brown up, suggesting dispersion around earnings.

No specific regional impact beyond US-listed peers’ reactions.

Limited, as the piece is focused on US earnings timing and peer reactions.

Counterpoint

Recent strength in RYAN and the segment may already reflect expectations, so a modest beat could still disappoint if growth remains near the low 1.8% YoY consensus.

Key entities

  • Ryan Specialty

    NYSE-listed specialty insurance broker scheduled to report Q2 earnings after market hours Thursday.

  • Marsh

    Professional services peer that reported Q2 with 6.2% YoY revenue growth and a post-results stock drop of 3.4%.

  • Brown & Brown

    Professional services peer that reported Q2 with 30.4% YoY revenue growth and a post-results stock gain of 8.7%.

Related articles

$RYANMedAI 8/10

Ryan Specialty posts Q2 revenue gain as E&S market slows

Ryan Specialty Holdings, Inc. reported second-quarter 2026 net commissions and fees of $902.7 million, up 7.4% year-over-year. Total revenue for the quarter reached $916.6 million, a 7.2% increase from $855.2 million a year earlier. Organic revenue growth came in at 6.7%, down from 7.1% in the prior-year period. The deceleration continues a trend across multiple quarters as the broader E&S market moderates.

$RYANMed

RYAN SPECIALTY HOLDINGS, INC. (RYAN): Results of Operations and Financial Condition

RYAN SPECIALTY HOLDINGS, INC. (RYAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ryan-20260630xex991.htm EX-99.1 RYAN-2026.06.30-EX 99.1 1 RYAN SPECIALTY REPORTS SECOND QUARTER 2026 RESULTS - Total Revenue grew 7.2% year-over-year to $916.6 million - - Organic Revenue Growth Rate* of 6.7% year-over-year - - Net Income of $108.4 million , or $0.33 pe

$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.